BGF MDI 320/14.4/9.6 μg
D5989C00001
Phase 3 small_molecule active
Quick answer
BGF MDI 320/14.4/9.6 μg for COPD (Chronic Obstructive Pulmonary Disease) is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- COPD (Chronic Obstructive Pulmonary Disease)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active